

NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET FORECAST 2018-2026

<https://marketpublishers.com/r/ND6E4622476EN.html>

Date: May 2018

Pages: 69

Price: US\$ 1,250.00 (Single User License)

ID: ND6E4622476EN

Abstracts

KEY FINDINGS

The North America Chronic Idiopathic Constipation Drug Market is expected to grow at a CAGR of 6.95% over the forecast period. The market value is expected to rise from \$xx million in 2017 and reach \$xx million by 2026. The changing modern dietary habits, chances of cancer or other systematic disease leading to CIC and the growing increasing elderly population are some of the factors driving the market

MARKET INSIGHTS

The North America chronic idiopathic constipation drug market is segmented on the basis of drug types and on the basis of the type of prescriptions. The drug type can be further divided into lubiprostone and linaclotide, with the former being a more popular drug. The prescription drug market can be further segmented into over the counter drugs and prescribed drugs. Continuous government initiatives and the already flourishing healthcare and medical industry in countries such as the United States and Canada are benefiting the CIC market growth in this region.

COMPETITIVE INSIGHTS

Some of the major players in the market include Chugai Pharmaceutical, Allergens, Synergy Pharmaceuticals, Ferring International Center S.A., Pfizer, GlaxoSmithKline, Roche Holding Ag, Merck Sharp & Dohme, Sanofi, Bayer Ag, Eli Lilly And Company, Sucampo Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Ironwood Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Valeant Pharmaceuticals International, Cosmo

Pharmaceuticals Sa, Theravance Biopharma Inc and Progenics
Pharmaceuticals Inc.

Contents

1. RESEARCH SCOPE

- 1.1. STUDY GOALS
- 1.2. SCOPE OF THE MARKET STUDY
- 1.3. WHO WILL FIND THIS REPORT USEFUL?
- 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

- 2.1. SOURCES OF DATA
 - 2.1.1. SECONDARY DATA
 - 2.1.2. PRIMARY DATA
- 2.2. TOP DOWN APPROACH
- 2.3. BOTTOM-UP APPROACH
- 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

- 3.1. MARKET SUMMARY

4. MARKET OVERVIEW

- 4.1. MARKET DEFINITION
- 4.2. KEY MARKET INSIGHTS
- 4.3. ATTRACTIVE INVESTMENT SCENARIO
- 4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
- 4.5. MARKET DRIVERS
 - 4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
 - 4.5.2. CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
 - 4.5.3. INCREASING ELDERLY POPULATION
 - 4.5.4. IMPROVED AND EFFICIENT DRUGS IN PIPELINE
 - 4.5.5. INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
- 4.6. RESTRAINTS
 - 4.6.1. SURGICAL TREATMENTS
 - 4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
- 4.7. OPPORTUNITIES

4.7.1. HIGH UNMET NEEDS

4.8. CHALLENGES

4.8.1. SIDE EFFECTS OF CIC DRUGS

5. NORTH AMERICA CIC DRUGS MARKET, BY DRUG TYPE 2018-2026 (\$ MILLION)

5.1. OVERVIEW

5.1.1. LUBIPROSTONE

5.1.2. LINACLOTIDE

5.1.3. OTHERS

5.2. PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, \$ MILLION)

5.3. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, \$ MILLION)

6. NORTH AMERICA CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

6.1. PRESCRIBED DRUGS

6.2. OVER THE COUNTER DRUGS

7. KEY ANALYTICS

7.1. PORTERS FIVE FORCE ANALYSIS

7.1.1. INTENSITY OF COMPETITIVE RIVALRY

7.1.2. BARGAINING POWER OF SUPPLIERS

7.1.3. BARGAINING POWER OF BUYERS

7.1.4. THREAT OF SUBSTITUTE PRODUCTS

7.1.5. THREAT OF NEW ENTRANTS

7.2. VENDOR LANDSCAPE

7.3. OPPORTUNITY MATRIX

8. NORTH AMERICA CIC DRUGS MARKET BY COUNTRIES 2018-2026 (\$ MILLION)

8.1. US

8.2. CANADA

9. COMPANY PROFILES

- 9.1. ALLERGENS
 - 9.1.1. OVERVIEW
 - 9.1.2. PRODUCT PORTFOLIO
 - 9.1.3. STRATEGIC MOVES
 - 9.1.4. SCOT ANALYSIS
- 9.2. CHUGAI PHARMACEUTICAL
 - 9.2.1. OVERVIEW
 - 9.2.2. PRODUCTS PORTFOLIO
 - 9.2.3. STRATEGIC MOVES
 - 9.2.4. SCOT ANALYSIS
- 9.3. FERRING INTERNATIONAL CENTER S.A.
 - 9.3.1. OVERVIEW
 - 9.3.2. PRODUCTS PORTFOLIO
 - 9.3.3. SCOT ANALYSIS
- 9.4. SYNERGY PHARMACEUTICALS
 - 9.4.1. OVERVIEW
 - 9.4.2. PRODUCTS PORTFOLIO
 - 9.4.3. SCOT ANALYSIS
- 9.5. PFIZER
 - 9.5.1. OVERVIEW
 - 9.5.2. PFIZER PRODUCT PORTFOLIO
 - 9.5.3. SCOT ANALYSIS
- 9.6. GLAXOSMITHKLINE
 - 9.6.1. OVERVIEW
 - 9.6.2. PRODUCT PORTFOLIO
 - 9.6.3. SCOT ANALYSIS
- 9.7. ROCHE HOLDING AG
 - 9.7.1. OVERVIEW
 - 9.7.2. PRODUCT PORTFOLIO
 - 9.7.3. STRATEGIC MOVES
 - 9.7.4. SCOT ANALYSIS
- 9.8. SANOFI
 - 9.8.1. OVERVIEW
 - 9.8.2. PRODUCTS PORTFOLIO
 - 9.8.3. SCOT ANALYSIS
- 9.9. BAYER AG
 - 9.9.1. OVERVIEW
 - 9.9.2. PRODUCTS PORTFOLIO

- 9.9.3. SCOT ANALYSIS
- 9.10. MERCK SHARP & DOHME
 - 9.10.1. OVERVIEW
 - 9.10.2. PRODUCT PORTFOLIO
 - 9.10.3. SCOT ANALYSIS
- 9.11. ELI LILLY AND COMPANY
 - 9.11.1. OVERVIEW
 - 9.11.2. PRODUCT PORTFOLIO
 - 9.11.3. SCOT ANALYSIS
- 9.12. SALIX PHARMACEUTICALS LTD
 - 9.12.1. OVERVIEW
 - 9.12.2. PRODUCT PORTFOLIO
 - 9.12.3. SCOT ANALYSIS
- 9.13. SUCAMPO PHARMACEUTICALS INC
 - 9.13.1. OVERVIEW
 - 9.13.2. PRODUCT PORTFOLIO
 - 9.13.3. SCOT ANALYSIS
- 9.14. IRONWOOD PHARMACEUTICALS INC
 - 9.14.1. OVERVIEW
 - 9.14.2. PRODUCT PORTFOLIO
 - 9.14.3. SCOT ANALYSIS
- 9.15. VALEANT PHARMACEUTICALS INTERNATIONAL
 - 9.15.1. OVERVIEW
- 9.16. DAIICHI SANKYO CO LTD
 - 9.16.1. OVERVIEW
 - 9.16.2. PRODUCT PORTFOLIO
 - 9.16.3. SCOT ANALYSIS
- 9.17. COSMO PHARMACEUTICALS SA
 - 9.17.1. OVERVIEW
 - 9.17.2. PRODUCT PORTFOLIO
 - 9.17.3. SCOT ANALYSIS
- 9.18. PROGENICS PHARMACEUTICALS INC
 - 9.18.1. OVERVIEW
 - 9.18.2. PRODUCT PORTFOLIO
 - 9.18.3. SCOT ANALYSIS
- 9.19. THERAVANCE BIOPHARMA INC
 - 9.19.1. OVERVIEW
 - 9.19.2. PRODUCT PORTFOLIO
 - 9.19.3. SCOT ANALYSIS

List Of Tables

LIST OF TABLES

TABLE 1 NORTH AMERICA CIC DRUG MARKET BY COUNTRIES 2018-2026 (\$ MILLION)

TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION

TABLE 3 CONSTIPATION IN PARKINSON'S DISEASE

TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION

TABLE 5 NORTH AMERICA CIC DRUGS MARKET BY DRUG TYPE 2018-2026 (\$ MILLION)

TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)

TABLE 7 PRODUCT PROFILE (LINACLOTIDE)

TABLE 8 PRODUCT PROFILE (BISACODYL)

TABLE 9 PIPELINE PRODUCT PROFILE (PLECANATIDE)

TABLE 10 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)

TABLE 11 NORTH AMERICA CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

TABLE 12 LINZESS PRECAUTIONS AND SIDE EFFECTS

TABLE 13 NORTH AMERICA CIC DRUGS MARKET BY COUNTRY 2018–2026 (\$ MILLION)

TABLE 14 U.S. CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

TABLE 15 U.S. CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 (\$ MILLION)

TABLE 16 CANADA CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 (\$ MILLION)

TABLE 17 CANADA CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 (\$ MILLION)

List Of Figures

LIST OF FIGURES

FIGURE 1 NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 2 NORTH AMERICA CIC DRUG MARKET BY DRUG TYPE 2018-2026 (\$ MILLION)

FIGURE 3 NORTH AMERICA CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2017 (\$ MILLION)

FIGURE 4 CAUSES OF CONSTIPATION

FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014

FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE

FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS

FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION

FIGURE 9 NEED OF SURGERY PROCESS

FIGURE 10 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM

FIGURE 11 NORTH AMERICA LUBIPROSTONE DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 12 NORTH AMERICA LINACLOTIDE DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 13 NORTH AMERICA OTHER DRUGS MARKET 2018-2026 (\$ MILLION)

FIGURE 14 NORTH AMERICA PRESCRIBED CIC DRUGS MARKET 2018-2026 (\$ MILLION)

FIGURE 15 NORTH AMERICA OVER THE COUNTER CIC DRUG MARKET 2018-2026 (\$ MILLION)

FIGURE 16 NORTH AMERICA CIC DRUGS MARKET 2018–2026 (\$ MILLION)

FIGURE 17 US CIC MARKET, 2018-2026 (\$ MILLION)

FIGURE 18 CANADA CIC MARKET 2018-2026 (\$ MILLION)

COMPANIES MENTIONED

1. ALLERGENS
2. CHUGAI PHARMACEUTICAL
3. FERRING INTERNATIONAL CENTER S.A.
4. SYNERGY PHARMACEUTICALS
5. PFIZER
6. GLAXOSMITHKLINE

7. ROCHE HOLDING AG
8. SANOFI
9. BAYER AG
10. MERCK SHARP & DOHME
11. ELI LILLY AND COMPANY
12. SALIX PHARMACEUTICALS LTD
13. SUCAMPO PHARMACEUTICALS INC
14. IRONWOOD PHARMACEUTICALS INC
15. VALEANT PHARMACEUTICALS INTERNATIONAL
16. DAIICHI SANKYO CO LTD
17. COSMO PHARMACEUTICALS SA
18. PROGENICS PHARMACEUTICALS INC
19. THERAVANCE BIOPHARMA INC

I would like to order

Product name: NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET FORECAST 2018-2026

Product link: <https://marketpublishers.com/r/ND6E4622476EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ND6E4622476EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

